Lantheus inks deal to market Definity in China
Lantheus Medical Imaging has formed a strategic relationship with Beijing Double-Crane Pharmaceuticals for the distribution and supply of Definity in China.

The boards of directors of both Lantheus and Beijing Double-Crane have approved a 15-year agreement for exclusive distribution and supply of Definity, an ultrasound contrast agent for use in in echocardiograms. Lantheus and Double-Crane plan to fully execute the agreement in the next several weeks in China.

Under the terms of the agreement, both parties will collaborate on confirmatory clinical trials to commercialize Definity in China for use in cardiac disease.

The agreement also provides Double-Crane the right of first negotiation to manufacture Definity in China upon the achievement of certain sales levels. In addition, Double-Crane has the right to negotiate the manufacture of Definity in China in the event Lantheus chooses to seek a Chinese manufacturing partner for the product.